Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca’s SATURN “Moon Shot” Pitting Crestor Against Lipitor Misses The Mark

Executive Summary

Top-line results from AstraZeneca’s SATURN trial in atherosclerosis seem unlikely to prevent erosion of Crestor’s (rosuvastatin) market share once generic versions of Pfizer’s Lipitor (atorvastatin) enter the market in November.
Advertisement

Related Content

Amid The Lipitor Scuffle, What’s Next For Crestor?
The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics
Battle Of The Blockbusters: Lipitor Vs. Crestor In Atherosclerosis Progression Study Begins
Battle Of The Blockbusters: Lipitor Vs. Crestor In Atherosclerosis Progression Study Begins

Topics

Advertisement
UsernamePublicRestriction

Register

PS053728

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel